JGJan Geurts

Jan Geurts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Geurts has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Periprosthetic fractures around chronically infected total hip arthroplasties: a case series and pragmatic two-stage treatment framework

    by Georges F. Vles, Willem-Jan Metsemakers, Laurens Aerden, Jan Geurts, Oliver Borens, Stijn Ghijselings

    Three periprosthetic femoral fractures around chronically infected total hip arthroplasties (THAs) were treated according to a pragmatic two-stage treatment framework. Infection control and fracture healing were achieved. This may serve as a reference for surgeons confronted with these complex and technically demanding situations.

  • Open Access

    The Antibacterial Properties of a Silver Multilayer Coating for the Prevention of Bacterial Biofilm Formation on Orthopedic Implants—An In Vitro Study

    by Sanne W. G. van Hoogstraten, Janine Fechter, Rainer Bargon, Julia L. van Agtmaal, Laura C. W. Peeters, Jan Geurts, Jacobus J. C. Arts

    The prevention of biofilm formation on orthopedic implants is essential, as biofilms are the main challenge in the effective treatment of periprosthetic joint infection (PJI). A silver multilayer (SML) coating was developed to prevent biofilm formation on the implant surface. Previous studies have already demonstrated its antibacterial properties without cytotoxic effects. However, the coating has not been previously tested when applied to common titanium surfaces used in total joint arthroplasty implants. These surfaces often have increased roughness and porosity in the case of cementless implants, which can alter the antibacterial effect of the coating. In this study, we assessed the antibacterial and anti-biofilm properties of the SML coating on corundum-blasted and plasma-sprayed microporous-coated titanium alloy surfaces, using S. aureus, S. epidermidis, and E. coli. An antibacterial activity test following the principles of ISO 22196, ASTM E2180-18, and JIS Z 2801 standards was performed, as well as a biofilm proliferation assay investigating bacterial adhesion and biofilm formation. The SML coating exhibited strong antibacterial effects for all bacterial strains. After 24 h biofilm culture, a >4-log reduction in CFU was induced by the SML coating for S. epidermidis and E. coli on the corundum-blasted and plasma-sprayed microporous-coated titanium surfaces, respectively, when compared to the uncoated surfaces. The coating showed bactericidal properties against Gram-positive bacteria on the corundum-blasted discs. The SML coating on two common titanium surfaces demonstrates significant potential as an effective strategy in combating PJI across a wide range of orthopedic implants.


  • Open Access

    Bioactive-Glass-Based Materials with Possible Application in Diabetic Wound Healing: A Systematic Review

    by Marian Vargas Guerrero, Floor M. A. Aendekerk, Candice de Boer, Jan Geurts, Jimmy Lucchesi, Jacobus J. C. Arts

    Diabetes affected 537 million adults in 2021, costing a total of USD 966 billion dollars in healthcare. One of the most common complications associated with diabetes corresponds to the development of diabetic foot ulcers (DFUs). DFUs affect around 15% of diabetic patients; these ulcers have impaired healing due to neuropathy, arterial disease, infection, and aberrant extracellular matrix (ECM) degradation, among other factors. The bioactive-glass-based materials discussed in this systematic review show promising results in accelerating diabetic wound healing. It can be concluded that the addition of BG is extremely valuable with regard to the wound healing rate and wound healing quality, since BG activates fibroblasts, enhances M1-to-M2 phenotype switching, induces angiogenesis, and initiates the formation of granulation tissue and re-epithelization of the wound. In addition, a higher density and deposition and better organization of collagen type III are seen. This systematic review was made using the PRISMA guideline and intends to contribute to the advancement of diabetic wound healing therapeutic strategies development by providing an overview of the materials currently being developed and their effect in diabetic wound healing in vitro and in vivo.


  • Open Access

    First-in-Human Integrated Use of a Dedicated Microsurgical Robot with a 4K 3D Exoscope: The Future of Microsurgery

    by Tom J. M. van Mulken, Shan S. Qiu, Yasmine Jonis, Jairo J. A. Profar, Taco J. Blokhuis, Jan Geurts, Rutger M. Schols, René R. W. J. van der Hulst

    Innovative techniques can help overcome the limitations of the human body. Operating on very small structures requires adequate vision of the surgical field and precise movements of sophisticated instruments. Both the human eye and hand are limited when performing microsurgery. Conventional microsurgery uses operation microscopes to enhance the visualization of very small structures. Evolving technology of high-definition 3D cameras provides the opportunity to replace conventional operation microscopes, thereby improving ergonomics for surgeons. This leaves the human hand as a limiting factor in microsurgery. A dedicated robot for microsurgery has been developed to overcome this limitation and enhance the precision and stability of the surgeons’ hands. We present the first-in-human case in reconstructive microsurgery where both technologies are integrated using a dedicated microsurgical robot in combination with a 4K 3D exoscope.


  • Antibiotic release from PMMA spacers and PMMA beads measured with ELISA: Assessment of in vitro samples and drain fluid samples of patients

    by Daniël M. C. Janssen, Paul Willems, Jan Geurts, Chris J. J. Arts

    For prosthetic joint infections, antibiotic loaded poly methyl methacrylate (PMMA) spacer or beads can be used to release high concentrations of antibiotics locally at the infection site, while minimizing systemic toxicity. The aim of this study is to determine in vitro and in vivo pharmacokinetic release profile of antibiotics from PMMA spacers and PMMA beads. For the in vitro experiment, the PMMA spacers or beads were submerged in phosphate‐buffered saline and gentamicin concentrations were determined from collected specimen at several times points, measured with enzyme‐linked immunosorbent assays (ELISA). To assess the in vivo antibiotic release profile of different spacers, wound drainage fluid samples were collected after implantation of a spacer over a period of maximum 14 days. After 48 h, the burst gentamicin concentration elution was 9862 ± 1782 ng/ml (mean ± SD) from spacers versus 38,394 ± 7071 ng/ml (mean ± SD) for beads. Over 35 days, spacers had eluted a cumulative mean concentration of 13,812 ± 3548 versus 55,048 ± 12,006 ng/ml for beads (p < 0.001). Clinical samples of patients with a Vancogenx® spacer showed higher gentamicin release than Refobacin™ spacers (p < 0.001). This is the first study that measured the release data of local antibiotics with ELISA. Compare to spacers, the exact release values of gentamicin from PMMA beads are more than 10 times higher and reached a maximum much later than spacers. This makes the use of PMMA beads more preferable to use for treatment of the infection itself.


  • Open Access

    Diagnostic value of hybrid FDG-PET/MR imaging of chronic osteomyelitis

    by Dennis Jan Willem Hulsen, Cristina Mitea, Jacobus J. Arts, Daan Loeffen, Jan Geurts

    Background: Magnetic resonance imaging (MRI) and 2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG) Positron Emission Tomography, paired with Computed Tomography (PET/CT) are commonly used modalities in the complicated diagnostic work-up of osteomyelitis. PET/MRI is a relatively novel hybrid modality with suggested applications in bone infection imaging, based on expert opinion and previous qualitative research. 18F-FDG PET/MRI has the advantages of reduced radiation dose, more soft tissue information, and is deemed more valuable for surgical planning compared to 18F-FDG PET/CT. The goal of this study is to quantitatively assess the diagnostic value of hybrid 18F-FDG PET/MRI for chronic osteomyelitis. Methods: A retrospective analysis was performed by a nuclear medicine physician and radiologist on 36 patients with 18F-FDG PET/MRI scans for suspected osteomyelitis. Sensitivity, specificity, and accuracy were determined with the clinical assessment by the orthopaedic surgeon (based on subsequent intraoperative microbiology or long-term follow-up) as the ground truth. Standardized uptake values (SUV) were measured and analysed by means of receiver operating characteristics (ROC). Results: This first study to quantitatively report the diagnostic value of 18F-FDG PET/MRI yielded a sensitivity, specificity, and accuracy of 78%, 100%, and 86% respectively. Area under the ROC curve was .736, .755, and .769 for the SUVmax, target to background ratio, and SUVmax_ratio respectively. These results are in the same range and not statistically different compared to diagnostic value for 18F-FDG PET/CT imaging of osteomyelitis in literature. Conclusions: Based on the aforementioned advantages of 18F-FDG PET/MRI and the diagnostic value reported here, the authors propose 18F-FDG PET/MRI as an alternative to 18F-FDG PET/CT in osteomyelitis diagnosis, if available.


  • Open Access

    Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study

    by Tom A. G. Van Vugt, Jeffrey Heidotting, Jacobus J. Arts, Joris J. W. Ploegmakers, Paul C. Jutte, Jan A. P. Geurts

    Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive®), chronic osteomyelitis can be treated in a one-stage procedure. This study evaluated the mid-term clinical results of patients treated with S53P4 bioactive glass for long bone chronic osteomyelitis. Methods: In this prospective multi-center study, patients from two different university medical centers in the Netherlands were included. One-stage treatment consisted of debridement surgery, implantation of S53P4 bioactive glass, and treatment with culture-based systemic antibiotics. If required, wound closure by a plastic surgeon was performed. The primary outcome was the eradication of infection, and a secondary statistical analysis was performed on probable risk factors for treatment failure. Results: In total, 78 patients with chronic cavitary long bone osteomyelitis were included. Follow-up was at least 12 months (mean 46; standard deviation, SD, 20), and 69 patients were treated in a one-stage procedure. Overall infection eradication was 85 %, and 1-year infection-free survival was 89 %. Primary closure versus local/muscular flap coverage is the only risk factor for treatment failure. Conclusion: With 85 % eradication of infection, S53P4 bioactive glass is an effective biomaterial in the treatment of chronic osteomyelitis in a one-stage procedure. A major risk factor for treatment failure is the necessity for local/free muscle flap coverage. These results confirm earlier published data, and together with the fundamentally different antimicrobial pathways without antibiotic resistance, S53P4 bioactive glass is a recommendable biomaterial for chronic osteomyelitis treatment and might be beneficial over other biomaterials.


  • Open Access

    Use of contemporary biomaterials in chronic osteomyelitis treatment: Clinical lessons learned and literature review

    by Jan A. P. Geurts, Tom A. G. van Vugt, Jacobus J. C. Arts

    Chronic osteomyelitis has always been a therapeutic challenge for patient and surgeon due to the specific problems related with bone infection and bacterial biofilm eradication. Other than being the cause of infection or facilitating spread or persistence of infection, biomaterials are also becoming a tool in the treatment of infection. Certain novel biomaterials have unique and ideal properties that render them perfectly suited to combat infection and are therefore used more and more in the treatment of chronic bone infections. In case of infection treatment, there is still debate whether these properties should be focused on bone regeneration and/or their antimicrobial properties. These properties will be of even greater importance with the challenge of emerging antimicrobial resistance. This review highlights indications for use and specific material properties of some commonly used contemporary biomaterials for this indication as well as clinical experience and a literature overview.


  • Open Access

    The Implantation of Bioactive Glass Granules Can Contribute the Load-Bearing Capacity of Bones Weakened by Large Cortical Defects

    by Nicole A. P. van Gestel, Floor Gabriels, Jan A. P. Geurts, Dennis J. W. Hulsen, Caroline E. Wyers, Joop P. van de Bergh, Keita Ito, Sandra Hofmann, Jacobus J. Arts, Bert van Rietbergen

    Bioactive glass (BAG) granules (S53P4) have shown good clinical results in one-stage treatment of osteomyelitis. During this treatment, a cortical window is created, and infected bone is debrided, which results in large defects that affect the mechanical properties of the bone. This study aimed to evaluate the role of BAG granules in load-bearing bone defect grafting. First, the influence of the geometry of the cortical window on the bone bending stiffness and estimated failure moments was evaluated using micro finite element analysis (µFE). This resulted in significant differences between the variations in width and length. In addition, µFE analysis showed that BAG granules contribute to bearing loads in simulated compression of a tibia with a defect grafted with BAG and a BAG and bone morsel mixture. These mixtures potentially can unload the cortical bone that is weakened by a large defect directly after the operation by up to approximately 25%, but only in case of optimal load transfer through the mixture.


  • Open Access

    Cost-Effectiveness Study of One-Stage Treatment of Chronic Osteomyelitis with Bioactive Glass S53P4

    by Jan Geurts, Tom van Vugt, Eline Thijssen, Jacobus J. Arts

    This study was set up to evaluate the costs of a one-stage treatment of chronic osteomyelitis using bioactive glass S53P4 versus a two-stage treatment using gentamicin-loaded PMMA beads. Furthermore, a cost-effectiveness analysis was performed from a hospital’s perspective together with the evaluation of clinical outcome. A treatment group (n = 25) receiving one-stage surgery with bioactive glass was retrospectively compared with a two-stage control group (n = 25). An assessment was made of all costs included from first outpatient visit until one year after treatment. Bootstrap simulation and sensitivity analyses were performed. The primary endpoint was cost-effectiveness with clinical outcome as the secondary endpoint. The base case analyses shows dominance of the one-stage treatment with bioactive glass S53P4 due to lower costs and a better clinical outcome. Sensitivity analyses confirm these findings. This study is the first in its kind to show one-stage treatment of chronic osteomyelitis with bioactive glass S53P4 to be cost-effective.